A Study of Olynth Saline/Ectomed Nasal Drops/Spray Based Upon Previous Usage

The purpose of this study is to proactively collect customer feedback on the performance aspects and risk factors of Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Common Cold Hypersensitivity Immune System Diseases Infections Nose Diseases Otorhinolaryngologic Diseases Paranasal Sinus Diseases Picornaviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Sinusitis Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Schlesinger Group

Berlin, D-10789, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged 18 years or older who has personally used or administered the nasal drops/spray to a child
Has personally used or administered to a child, the Nasal Drops/Spray at least once within the past 6 months
Able to read, write, speak, and understand German
Has internet access to complete an on-line survey
Intends to complete the survey
Individual has signed the informed consent document (ICD)

Exclusion criteria

Is an employee/contractor or immediate family member of the principal investigator (PI), Schlesinger group, product perceptions limited (PPL) Insights or sponsor of this study

Treatment and study plan

Primary outcomes

Participant Feedback on the Performance Aspects of Olynth Nasal Saline Drops

Time frame: Up to 1 month and 14 days

Participant feedback on the performance aspects of Olynth Nasal Saline Drops will be assessed via electronic survey.
Participant Feedback on the Performance Aspects of Olynth Nasal Saline Spray

Time frame: Up to 1 month and 14 days

Participant feedback on the performance aspects of Olynth Nasal Saline Spray will be assessed via electronic survey.
Participant Feedback on the Performance Aspects of Olynth Ectomed Nasal Spray

Time frame: Up to 1 month and 14 days

Participant feedback on the performance aspects of Olynth Ectomed Nasal Spray will be assessed via electronic survey.
Number of Participants with Adverse Events (AEs)

Time frame: Up to 1 month and 14 days

An AE is any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, whether or not related to the investigational device.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer Inc. (J&JCI)

Industry

Registry information

Official study title

A Non-Interventional Clinical Study to Assess the Risk and Performance Aspects of Olynth Saline/Ectomed Nasal Drops/Spray Based Upon Previous Usage

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Nov 19, 2021
Registry last updated: Feb 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed